Alain Piche

Prof. Alain Piche

Department of Microbiology and Infectiology, University of Sherbrooke, 3001, 12ième Avenue Nord, Sherbrooke, Quebec, J1H 5N4, Canada.
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2011 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DLDenis Lane
Denis Lane
IMIsabelle Matte
Isabelle Matte
CRClaudine Rancourt
Claudine Rancourt
Alain PicheAlain Piche
Alain Piche
Background: The acellular fraction of epithelial ovarian cancer (EOC) ascites promotes de novo resistance of tumor cells and thus supports the idea that tumor cells may survive in the surrounding protective microenvironment contributing to disease recurrence. Levels of the pro-inflammatory cytokines IL-6 and IL-8 are elevated in EOC ascites suggesting that they could play a role in tumor progression. Methods: We measured IL-6 and IL-8 levels in the ascites of 39 patients with newly diagnosed EOC. Commercially available enzyme-linked immunosorbent assay (ELISA) was used to determine IL-6 and IL-8 ascites levels. Ascites cytokine levels were correlated with clinicopathological parameters and progression-free survival. Results: Mean ascites levels for IL-6 and IL-8 were 6419 pg/ml (SEM: 1409 pg/ml) and 1408 pg/ml (SEM: 437 pg/ml) respectively. The levels of IL-6 and IL-8 in ascites were significantly lower in patients that have received prior chemotherapy before the surgery (Mann-Whitney U test, P = 0.037 for IL-6 and P = 0.008 for IL-8). Univariate analysis revealed that high IL-6 ascites levels (P = 0.021), serum CA125 levels (P = 0.04) and stage IV (P = 0.009) were significantly correlated with shorter progression-free survival. Including these variables in a multivariate analysis revealed that elevated IL-6 levels (P = 0.033) was an independent predictor of shorter progression-free survival. Conclusion: Elevated IL-6, but not IL-8, ascites level is an independent predictor of shorter progression-free survival.

1 January 2012
Verified
Journal Article
Closed access
IMIsabelle Matte
Isabelle Matte
DLDenis Lane
Denis Lane
CLClauDe laplante
ClauDe laplante
CRClaudine Rancourt
Claudine Rancourt
Alain PicheAlain Piche
Alain Piche

27 March 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
CPCecile Le Page
Cecile Le Page
KRKurosh Rahimi
Kurosh Rahimi
MKMartin Köbel
Martin Köbel
PTPatricia N. Tonin
Patricia N. Tonin
LMLiliane Meunier
Liliane Meunier
AMAnne-Marie Mes-Masson
Anne-Marie Mes-Masson
Ovarian carcinoma is the most lethal gynecological malignancy due to early dissemination and acquired resistance to platinum-based chemotherapy. Reliable markers that are independent and complementary to clinical parameters are needed to improve the management of patients with this disease. The Canadian Ovarian Experimental Unified Resource (COEUR) provides researchers with biological material and associated clinical data to conduct biomarker validation studies. Using standards defined by the Canadian Tissue Repository Network (CTRNet), we have previously demonstrated the quality of the biological material from this resource. Here we describe the clinical characteristics of the COEUR cohort. With support from 12 Canadian ovarian cancer biobanks in Canada, we created a central retrospective cohort comprised of more than 2000 patient tissue samples with associated clinical data, including 1246 high-grade serous, 102 low-grade serous, 295 endometrioid, 259 clear cell and 89 mucinous carcinoma histotypes. A two-step reclassification process was applied to assure contemporary histological classification (histotyping). For each histotypes individually, we evaluated the association between the known clinico-pathological parameters (stage, cytoreduction, chemotherapy treatment, BRCA1 and BRCA2 mutation) and patient outcome by using Kaplan-Meier and Cox proportional hazard regression analyses. The median follow-up time of the cohort was 45 months and the 5-year survival rate for patients with high-grade serous carcinomas was 34%, in contrast to endometrioid carcinomas with 80% at 5 years. Survival profiles differed by histotype when stratified by stage or cytoreduction. Women with mucinous or clear cell carcinomas at advanced stage or with non-optimally debulked disease had the worst outcomes. In high-grade serous carcinoma, we observed significant association with longer survival in women harboring BRCA1 or BRCA2 mutation as compared to patients without detectable mutation. Our results show the expected survival rates, as compared with current literature, in each histotype suggesting that the cohort is an unbiased representation of the five major histotypes. COEUR, a one stop comprehensive biorepository, has collected mature outcome data and relevant clinical data in a comprehensive manner allowing stratified analysis.

15 February 2011 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MCM Comamala
M Comamala
MPM Pinard
M Pinard
CTC Thériault
C Thériault
IMI Matte
I Matte
AAA Albert
A Albert
CRC Rancourt
C Rancourt
Epithelial ovarian cancer (EOC) cells are prone to metastasise throughout the peritoneal cavity. The epithelial-to-mesenchymal transition (EMT) is a necessary step towards metastatic tumour progression. CA125/MUC16 mucin is a high-molecular-weight glycoprotein overexpressed in the majority of serous carcinomas, suggesting a possible role in the pathogenesis of these cancers. The role of CA125/MUC16 in EMT was investigated using single-chain antibody-mediated knockdown of cell surface CA125/MUC16 in overexpressing EOC NIH:OVCAR3 cells. CA125/MUC16 knockdown was associated with morphological alterations along with decreased surface expression of epithelial markers (E-cadherin, cytokeratin-18) and increased expression of mesenchymal markers (N-cadherin, vimentin). Co-immunoprecipitation experiments revealed that CA125/MUC16 binds to E-cadherin and β-catenin complexes. The in vitro studies showed disruption of cell–cell junctions, enhanced motility, migration and invasiveness in CA125/MUC16 knockdown cells. Enhanced epidermal growth factor receptor (EGFR) activation was observed in CA125/MUC16 knockdown cells along with increased Akt and ERK1/2 phosphorylation, which are downstream effectors of EGFR, and increased MMP-2 and MMP-9 expression and activities. Epidermal growth factor receptor inhibition strongly inhibited the motility of CA125/MUC16 knockdown cells. Our findings suggest that CA125/MUC16 plays a role in EMT, presumably through its interaction with E-cadherin and β-catenin complexes and by modulating EGFR and its downstream signalling pathway in NIH:OVCAR3 cells.

19 April 2010 in Oncogene
Verified
Journal Article
Closed access
DLD Lane
D Lane
NGN Goncharenko-Khaider
N Goncharenko-Khaider
CRC Rancourt
C Rancourt
Alain PicheAlain Piche
Alain Piche

23 July 2007 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
DLDenis Lane
Denis Lane
VRVéronique Robert
Véronique Robert
RGRoxanne Grondin
Roxanne Grondin
CRClaudine Rancourt
Claudine Rancourt
Alain PicheAlain Piche
Alain Piche
Ascites are commonly found in ovarian cancer patients with advanced disease and are rich in cellular components and growth‐promoting factors. The purpose of this study was to assess the effect of malignant ascites on TRAIL‐induced apoptosis. We demonstrate that malignant ascites obtained from women with advanced ovarian cancer protect tumor cells from TRAIL‐ and FasL‐induced apoptosis but not against cisplatin‐induced apoptosis. This antiapoptotic effect was consistently found among different malignant ascites while nonmalignant peritoneal fluids or conditioned medium from TRAIL‐resistant cells failed to protect tumor cells against TRAIL killing. Malignant ascites strongly inhibits TRAIL‐induced caspase‐3 activation and PARP cleavage. Furthermore, ascites activate PI3K and its downstream target Akt and increases c‐FLIPS protein levels without affecting ERK phosphorylation status. The antiapoptotic effect of malignant ascites is abrogated by the inhibition of PI3K with LY294002, by a specific inhibitor of Akt and by Akt siRNA. We further show that the pro‐survival effect of ascites can be suppressed by down‐regulation of c‐FLIPS. Our data indicate that malignant effusions protect against TRAIL‐induced apoptosis by activating the PI3K/Akt pathway. These findings demonstrate that the tumor microenvironment may contribute to the resistance of ovarian cancer cells to death receptor‐induced apoptosis.